Status:
COMPLETED
A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
44-79 years
Phase:
PHASE2
Brief Summary
To determine the efficacy and safety of intravitreal triamcinolone acetonide for refractory diabetic macular edema.
Detailed Description
Overall 80% of diabetic patients with low vision are in the nonproliferative stage and the main cause of decreased visual acuity is macular edema. According to the early treatment diabetic retinopath...
Eligibility Criteria
Inclusion
- Clinically significant macular edema(CSME)
- Clinically significant macular edema(CSME)refractory to initial or supplemental macular photocoagulation
Exclusion
- Mono-ocular patients
- History of vitrectomy
- Glaucoma or ocular hypertension
- Significant media opacity
- Traction on the macula
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2003
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00369863
Start Date
June 1 2002
End Date
June 1 2003
Last Update
February 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labbafinejad Medical Center
Tehran, Tehran Province, Iran, 16666